Arcus Biosciences Inc
NYSE:RCUS
Arcus Biosciences Inc
Revenue
Arcus Biosciences Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Arcus Biosciences Inc
NYSE:RCUS
|
Revenue
$117m
|
CAGR 3-Years
15%
|
CAGR 5-Years
69%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Arcus Biosciences Inc
Revenue Breakdown
Breakdown by Geography
Arcus Biosciences Inc
Breakdown by Segments
Arcus Biosciences Inc
Total Revenue:
117m
USD
|
License And Development Services Revenue:
80m
USD
|
License And R&D Services:
79m
USD
|
Other Collaboration Revenue:
37m
USD
|
Access Rights:
33m
USD
|
R&D Services:
5m
USD
|
See Also
What is Arcus Biosciences Inc's Revenue?
Revenue
117m
USD
Based on the financial report for Dec 31, 2023, Arcus Biosciences Inc's Revenue amounts to 117m USD.
What is Arcus Biosciences Inc's Revenue growth rate?
Revenue CAGR 5Y
69%
Over the last year, the Revenue growth was 4%. The average annual Revenue growth rates for Arcus Biosciences Inc have been 15% over the past three years , 69% over the past five years .